Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials

Documenti analoghi

• Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
  di: Lixin Guo, et al.
  Pubblicazione: (2024)
• SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST , a novel, decentralised, register‐based randomised trial on prevention of diabetic complications
  di: Jan W. Eriksson, et al.
  Pubblicazione: (2025)
• Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial
  di: Nan Yu, et al.
  Pubblicazione: (2025)
• Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin
  di: Jianglan Long, et al.
  Pubblicazione: (2024)
• Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  di: Yao Wang, et al.
  Pubblicazione: (2024)